| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.2 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.2 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.087 | 0.2 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |